The 10 year-survival rate for patients with PMF is believed to be less than 20%. The most common causes of death in patients with PMF are infections, hemorrhage, cardiac failure, postsplenectomy mortality, and transformation into acute leukemia.
Drug therapy for PMF has historically lacked disease-modifying activity. Allogenic hematopoietic stem cell transplant (allo-HCT) is the only current treatment option for PMF with curative potential; however, only a minority of patients are eligible for this intensive therapy. Patients with intermediate or high-risk PMF who are not eligible for transplant may be entered into a clinical trial or treated with a Janus kinase (JAK) inhibitor.
Learn more about treatment options for patients with PMF.
Medscape © 2020 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Emmanuel C. Besa. Fast Five Quiz: Prognosis of Primary Myelofibrosis - Medscape - Jul 16, 2020.